In vitro systems have inherent limitations in their ability to model whole organism gene responses, which must be identified and appropriately considered when developing predictive biomarkers of in vivo toxicity. Systematic comparison of in vitro and in vivo temporal gene expression profiles were conducted to assess the ability of Hepa1c1c7 mouse hepatoma cells to model hepatic responses in C57BL/6 mice following treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).
Background
Advances in microarray and related technologies continue to revolutionize biomedical research and are being incorporated into toxicology and risk assessment. These technologies not only facilitate a more comprehensive elucidation of the mechanisms of toxicity, but also support mechanistically-based quantitative risk assessment [1] [2] [3] [4] [5] . In addition, these technologies are being used to develop predictive toxicity screening assays to screen drug candidates with adverse characteristics earlier in the development pipeline in order to prioritize resources and maximize successes in clinical trials [6] [7] [8] . Comparable screening strategies are also being proposed to rank and prioritize commercial chemicals, natural products, and environmental contaminants that warrant further toxicological investigation. Traditionally, rodent models or sur-rogates for ecologically-relevant species are typically used in regulatory testing. However, public and regulatory pressure, especially in Europe, seek to minimize the use of animals in testing [9] . Similar policies in the US, such as the ICCVAM Authorization Act of 2000, provide guidelines to facilitate the regulatory acceptance of alternative testing methods. These initiatives combined with the need to assess an expanding list of drug candidates and commercial chemicals for toxicity, have increased demand for the development and implementation of high-throughput in vitro screening assays that are predictive of toxicity in humans and ecologically-relevant species.
Various in vitro hepatic models including the isolated perfused liver, precision cut liver slices, isolated primary liver cells and a number of immortalized liver cell lines, have been used as animal alternatives [10] . In addition to providing a renewable model, in vitro systems are a cost-effective alternative and are amenable to high-throughput screening. These models, particularly immortalized cell lines, also allow for more in-depth biochemical and molecular investigations, such as over-expression, knockdown, activation or inhibition strategies, thus further elucidating mechanisms of action. However, inherent limitations in the ability of cell cultures to model whole organism responses must also be considered when identifying putative biomarkers for high-throughput toxicity screening assays, and elucidating relevant mechanisms of toxicity that support quantitative risk assessment. Despite several in vitro toxicogenomic reports [11] [12] [13] , few have systematically examined the ability of in vitro systems to predict in vivo gene expression profiles in response to chemical treatment [10, 14] .
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a widespread environmental contaminant that elicits a number of adverse effects including tumor promotion, teratogenesis, hepatotoxicity, and immunotoxicity as well as the induction of several metabolizing enzymes [15] . Many, if not all of these effects, are due to alterations in gene expression mediated by the aryl hydrocarbon receptor (AhR), a basic-helix-loop-helix-PAS (bHLH-PAS) transcription factor [15, 16] . Ligand binding to the cytoplasmic AhR complex triggers the dissociation of interacting proteins and results in the translocation of the ligandbound AhR to the nucleus where it heterodimerizes with the aryl hydrocarbon receptor nuclear translocator (ARNT), another member of the bHLH-PAS family. The heterodimer then binds specific DNA elements, termed dioxin response elements (DREs), within the regulatory regions of target genes leading to changes in expression that ultimately result in the observed responses [17] . Although the role of AhR is well established, the gene regulatory pathways responsible for toxicity are poorly understood and warrant further investigation to assess the Number of genes differentially regulated (P1(t) > 0.9999 and Ifold changel > 1.5-fold) as measured by microarray analysis for the (A) time course and (B) and dose-response studies in mouse hepatoma Hepa1c1c7 cells 
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potential risks to humans and ecologically relevant species.
Hepa1c1c7 cells and C57BL/6 mice are well-established models routinely used to examine the mechanisms of action of TCDD and related compounds. In this study, TCDD-elicited temporal gene expression effects were systematically compared in order to assess the ability of Hepa1c1c7 cells to replicate C57BL/6 hepatic tissue responses. Our results indicate that several phase I and II metabolizing enzyme responses are aptly reproduced. However, many responses were model-specific and reflect inherent in vitro and in vivo differences that must be considered in mechanistic studies and during the selection of biomarkers for developing toxicity screening assays.
Results

In vitro microarray data analysis
Temporal gene expression profiles were assessed in Hepa1c1c7 wild type cells following treatment with 10 nM TCDD using cDNA microarrays with 13,362 spotted features. Empirical Bayes analysis of the in vitro time course data identified 331 features representing 285 unique genes with a P1(t) value greater than 0.9999 at one or more time points, and differential expression greater than ± 1.5 fold relative to time-matched vehicle controls. The number of differentially regulated genes gradually increased from 1 to 24 hrs, followed by a slight decrease at 48 hrs ( Figure 1A) . In vitro dose-response data performed at 12 hrs with TCDD covering 6 different concentrations (0.001, 0.01, 0.1, 1.0, 10 and 100 nM), identified 181 features representing 155 unique genes (P1(t) > 0.9999 and an absolute fold change > 1.5 at one or more doses; Figure 1B ). Complete in vitro time course and doseresponse data are available in Additional file 1 and 2, respectively.
As a control, the gene expression effects elicited by 10 nM TCDD in ARNT-deficient c4 Hepa1c1c7 mutants [18] were examined at 1 and 24 hrs (data not shown). Only ATPase, H+ transporting, V1 subunit E-like 2 isoform 2 (Atp6v1e2) and SUMO/sentrin specific peptidase 6 (Senp6) exhibited a significant change in expression using the same criteria (P1(t) > 0.9999 and an absolute fold change > 1.5). Neither Atp6v1e2 nor Senp6 were among the active genes in wild-type Hepa1c1c7 cells or in C57BL/ 6 liver samples [19] . These results provide further evidence that the AhR/ARNT signaling pathway mediates TCDD-elicited gene expression responses, which are consistent with in vivo microarray results with AhR knockout mice [20] .
Hierarchical clustering of the genes expressed in Hepa1c1c7 time course indicate that 2 and 4 hrs were most similar, as were 8 and 12 hrs, and 24 and 48 hrs, while the 1 hr time point was segregated ( Figure 2A) . A strong dose-response relationship was also evident with clusters sequentially branching out with increasing concentration ( Figure 2B ). At 12 hrs, 117 genes were differentially expressed with 112 exhibiting a dose-dependent response. Moreover, the fold changes measured in both the time course and dose-response studies using 10 nM TCDD were comparable. For example, xanthine dehydrogenase (Xdh) and NAD(P)H dehydrogenase, quinone 1 (Nqo1) were induced 2.39-and 4.89-fold respectively in the time course and 2.93-and 4.71-fold in the doseresponse study. There is a strong correlation (R = 0.97) between the differentially expressed genes at 12 hrs in the time course with the differentially regulated genes in the dose-response study at 10 nM, demonstrating the reproducibility between independent studies and providing further evidence that these genes are regulated by TCDD.
The list of temporally regulated genes was subjected to kmeans clustering using the standard correlation distance metrics. Five k-means clusters best characterized the dataset and identified clusters representing A) up-regulated early and sustained, B) up-regulated intermediate and sustained, C) up-regulated intermediate, D) up-regulated immediate and E) down-regulated late ( Figure 3 ). These were comparable to the k-means clusters identified in hepatic tissue of C57BL/6 mice following treatment with 30 µg/kg TCDD [19] . Although, no discernable functional category is over-represented in any one cluster, the sustained up-regulation of early (Cluster A) and intermediate (Cluster B) responding genes include classic TCDDresponsive genes such as cytochrome P450, family 1, subfamily a, polypeptide 1 (Cyp1a1), Xdh and Nqo1. Many down-regulated late genes were associated with cell cycle regulation such as myelocytomatosis oncogene (Myc). Additionally, targets of Myc, including cyclin D1 and ornithine decarboxylase (Odc1), were also down-regulated suggesting a mechanism for cell cycle arrest [21] [22] [23] , a common in vitro response to TCDD.
Classification of gene expression responses for common regulated genes
Using the same filtering criteria (P1(t) > 0.9999 and an absolute fold change > 1.5), 678 features representing 619 unique genes were differentially expressed as previously reported in a time course study conducted in hepatic tissue from C57BL/6 mice orally gavaged with 30 µg/kg TCDD [19] . The number of responsive in vivo genes and their temporal expression patterns closely paralleled the results from this in vitro study. The fewest number of active genes was observed at 2 hrs, followed by a large increase at 4 hrs, which was sustained to 72 hrs. However, the substantial increase in expressed in vivo genes at 168 hrs was attributed to triglyceride accumulation and immune cell infiltration, which was not observed in Hepa1c1c7 cells.
This list of 619 of in vivo genes served as the basis for subsequent comparisons against TCDD-elicited in vitro responses.
Comparison of in vitro and in vivo differentially expressed gene lists identified common and model specific responses ( Figure 4A ). TCDD treatment resulted in a total of 838 regulated genes in either model and with 67 common to both. TCDD elicited 218 gene expression changes unique to Hepa1c1c7 cells while 552 genes were specific to C57BL/6 hepatic samples. Although 67 genes were regulated in both models, not all possessed similar temporal patterns of expression. Contingency analysis using a 2 × 2 table and the χ 2 test resulted in a p-value < 0.001 (α = 0.05) illustrate a statistically significant association between the lists of differentially regulated genes in vitro and in vivo. Further stratification revealed genes that were either induced in both models (class I), repressed in both models (class II), induced in vivo while repressed in vitro (class III), or repressed in vivo while induced in vitro (class IV; Figure 4B ). Genes regulated in a similar fashion in both models (classes I and II) accounted for 49 of the 67 common active genes, while the remaining genes exhibited divergent expression profiles (classes III and IV). Hierarchical clustering of the temporal expression values for the 67 overlapping genes identified the same four classes ( Figure 4C ). The pattern across model and time illustrates that the earliest time points (i.e. 1 hr in vitro and 2 hr in vivo time points) cluster together while the remaining clusters branch into in vitro or in vivo clusters according to time. These results suggest that potential biomarkers of acute TCDD-mediated responses may best be predicted by the immediate-early in vitro gene responses.
In vitro and in vivo induced genes (class I) include xenobiotic and oxidoreductase enzymes such as abhydrolase domain containing 6 (Abhd6), Cyp1a1, dehydrogenase/ reductase (SDR family) member 3 (Dhrs3), Nqo1, prostaglandin-endoperoxide synthase 1 (Ptgs1), UDP-glucose dehydrogenase (Ugdh) and Xdh (Table 1 ). These genes have previously been reported to be TCDD-responsive [19, 24] , with Cyp1a1 and Nqo1 being members of the "AhR gene battery" [25] . Glutathione S-transferase, alpha 4 (Gsta4) was also induced in vitro and in vivo, 1.7-and 2.0-fold respectively, consistent with TCDD-mediated induction of phase I and II metabolizing enzymes. Of the 35 genes responding similarly in both models, approximately 71% of were similarly up-regulated (class I) while the remaining genes were repressed across both models (class II). Repressed class II genes include minichromosome maintenance deficient 6 (Mcm6), glycerol kinase (Gyk) and ficolin A (Fcna) (repressed 1.6-, 1.6-and 1.7fold in vitro, respectively). Overall, repressed genes did not share any common discernable biological function.
Forty-two of the 67 common differentially expressed genes were dose responsive at 12 and 24 hrs in vitro and in vivo, respectively, further suggesting the role of the AhR in mediating these responses. Microarray-based EC 50 values spanned at least 3 orders of magnitude ranging from 0.05 µg/kg to >150 µg/kg in vivo, and 0.00118 nM to 2.4 nM in vitro (Table 1) In addition to the regulated genes common to both models, 218 in vitro-and 559 in vivo-specific genes were identified. Many of the unique in vitro responses are involved in cell cycle regulation, including cyclins D1 and B2 ( Table 2) . Cyclin D1, which complexes with cyclindependent kinase 4 (Cdk4) to regulate the progression from G 1 to S phase [31, 32] , was down-regulated early and repressed 1.7-fold to 48 hrs. Furthermore, cyclin B2 and cell division cycle 2 homolog A (Cdc2a) which interact to form an active kinase required for G 2 promotion, were down-regulated, 1.8-fold and 1.5-fold, respectively. In addition to cell cycle related genes, UDP glucuronosyltransferase 1 family, polypeptide A2 (Ugt1a2), a phase II metabolizing enzyme, was induced 2.8-fold in vitro, but not significantly regulated in vivo.
Analysis of the C57BL/6 hepatic time course identified 552 unique genes that were solely regulated in vivo. This included TCDD induced transcripts for microsomal epoxide hydrolase 1 (Ephx1) and carbonyl reductase 3 (Cbr3) which both function as xenobiotic metabolizing enzymes. Notch gene homolog 1 (Notch1) and growth arrest specific 1 (Gas1) which are both associated with development and differentiation but serve undetermined roles in the liver, were also induced by TCDD (Table 3) . Genes related to immune cell accumulation were also specific to the in vivo study, coincident with immune cell accumulation at 168 hr as determined by histopathological examination [19] .
Comparison of basal gene expression levels in Hepa1c1c7 cells and hepatic tissue
In order to further investigate differences in gene expression levels, Hepa1c1c7 cells and C57BL/6 liver samples were directly compared by competitive hybridization on the same array, to identify basal gene expression level differences. Subsequent linear regression analysis of the mean normalized signal intensities from the untreated samples resulted in a correlation value of R = 0.75 ( Figure  5 ), which is consistent with basal gene expression comparisons of various in vitro rat hepatic systems against whole livers, where correlation values decreased between liver slices (R = 0.97), primary cells (R = 0.85), BRL3A (R = 0.3) and NRL clone 9 (R = 0.32) rat liver cell lines [10] .
Overall, the correlation illustrates reasonable concordance in basal gene expression levels between the two models. However, data points which deviate from the fitted line indicate differences in the basal expression of individual genes between the Hepa1c1c7 cells and hepatic tissue from C57BL/6 mice. Although there are differences, they may be negligible if the TCDD-elicited responses are conserved in vitro and in vivo. Complete microarray data for the untreated comparisons are available in Additional file 5.
The relative basal expression of the 67 common active features was further investigated ( Figure 5 ). In general, class I (i.e. induced in both models) genes fell close to the regression line, indicating that the basal expression of induced genes were comparable as were their in vitro and in vivo responses to TCDD. In contrast, basal expression levels of class III genes (i.e. induced in vivo while repressed in vitro) were generally higher in the Hepa1c1c7 cells, while levels in class II and IV (i.e. repressed in both models and repressed in vivo while induced in vitro, respectively) genes were scattered around the fitted linear line in Figure 5 .
Hierarchical clustering of the differentially regulated gene lists for A) temporal and B) dose-response microarray studies in mouse hepatoma Hepa1c1c7 cells Time (hrs) Dose (nM)
Quantitative real-time PCR verification of microarray responses
In total, 14 in vitro and 24 in vivo responsive genes representing common and model-specific genes were verified by quantitative real-time PCR (QRTPCR) (see Additional file 6). Of the selected genes regulated in both models, all displayed temporal patterns comparable to the microarray data ( Figure 6 ). For example, Xdh, Myc and fatty acid binding protein (Fabp5) exhibited good agreement in fold change and temporal expression pattern when comparing microarray and QRTPCR data. However, significant data compression was evident when comparing in vitro and in vivo Cyp1a1 induction by QRTPCR, although in vitro and in vivo microarray induction levels were comparable. Previous studies suggest this is likely due to the limited fluorescence intensity range (0 -65,535) of microarrays resulting in signal saturation and compres-sion of the true magnitude of induction of transcript levels [33, 34] . Cross hybridization of homologous probes to a given target sequence on the microarray may also be a contributing factor, especially in comparison to other, more gene-specific measurement techniques [35] .
Discussion
Microarrays have become an invaluable tool in toxicogenomics for comprehensively characterizing gene expression responses following treatment with an environmental contaminant, commercial chemical, natural product or drug as well as for investigating complex mixtures relevant to human and wildlife exposures. An emerging consensus suggests that toxicogenomics will accelerate drug development and significantly improve quantitative risk assessments [36, 37] . In addition, toxicogenomics supports the development and refinement of K-means clustering of temporally differentially regulated genes in vitro Figure 4B f Time point representing the maximum |fold change| Table 1 
: Classification of common differentially regulated temporal gene expression responses to TCDD in both in vitro and in vivo models (Continued)
predictive in vitro high-throughput toxicity screening assays that can be used as alternatives to traditional in vivo testing. Ideally, in vitro high-throughput toxicity screens can be used to rank and prioritize drug candidates, environmental contaminants, and commercial chemicals, which warrant further development or testing. Although in vitro responses are assumed to reflect a subset of comparable in vivo responses, few studies have completed a comprehensive and systematic comparison. This study closely examined two well-established models, and comprehensively compared the TCDD-elicited gene expression to assess the predictive value of in vitro systems.
Comparative analysis of Hepa1c1c7 cell and hepatic C57BL/6 microarray data identified 67 differentially expressed genes co-regulated by TCDD. Four classes based on their temporal expression patterns were identified (Figure 4B and 4C) , with 42 of the 67 common regulated genes exhibiting dose-response characteristics in both models. In vitro EC 50 values ranged from 0.001182 nM to 2.4 nM, while in vivo the values ranged from 0.05 µg/kg to >150 µg/kg. The wide range of EC 50 values illustrate the varying sensitivity of regulated genes to TCDD in both models.
Hepa1c1c7 cells and hepatic tissue from C57BL/6 mice are the prototypical models used to investigate the mechanisms of action of TCDD and other related compounds and both exhibited the classic induction of phase I and II metabolizing enzymes including Cyp1a1 and Nqo1 [38, 39] . Gsta4 and Xdh were also up-regulated in both models further demonstrating Hepa1c1c7 cells as a suitable model for investigating TCDD-regulated induction of xenobiotic metabolizing genes. In addition to these genes, the responses of Nqo1, Ugdh and Tnfaip2 were also conserved across models and were categorized as class I genes (similarly induced in both models; Figure 4B and 4C). However, Gsta2 was induced in vivo while no significant effect was detected in Hepa1c1c7 cells, and Ugt1a2 was induced in vitro but not differentially expressed in C57BL/ 6 hepatic tissue. Although many phase I and II metabolizing enzyme responses were conserved, differences exist that may limit Hepa1c1c7 cells from accurately modeling the full spectrum of in vivo hepatic responses elicited by TCDD.
A direct comparison of untreated Hepa1c1c7 cells and C57BL/6 hepatic tissue was performed to further investigate innate differences between the two models. Comparison of the normalized signal intensities revealed a good correlation (R = 0.75) between in vitro and in vivo basal expression levels ( Figure 5 ). This illustrates that many genes are basally expressed to similar levels in both models as illustrated by the cluster of class I (similarly induced genes) closely surrounding the fitted line. Although a cor-relation exists, there are still differences in basal expression which may be associated with the origins of the models (i.e. normal hepatic tissue versus hepatoma derived Hepa1c1c7 cells), as well as the inability of in vitro systems to effectively model complex interactions between different cell types (e.g. Kupffer and stellate cells). For example, Myc, a G 1 to S phase cell cycle regulator [23, [26] [27] [28] [29] , was repressed in vitro while being induced in vivo and the model-specific responses may be related to difference in basal expression levels between the two models ( Table 1 ). The levels of Myc transcripts in untreated Hepa1c1c7 cells were higher relative to untreated C57BL/6 hepatic tissue, consistent with the proliferative state of the in vitro system (data not shown). Examination of other class III genes suggests that they are more highly expressed in vitro when compared to in vivo ( Figure 5 ). Consequently, differences in basal expression may be a factor contributing to divergent in vitro -in vivo responses. Another possible source for the model-specific responses may be related to DNA methylation status of the promoter region of TCDD-responsive genes in either model. DNA methylation results in gene silencing [40, 41] and a previous study with Hepa1c1c7 has shown that TCDD-elicited gene expression responses are influenced by DNA methylation status [42] . The differing methylation states between the in vitro and in vivo systems may further contribute to the model-specific gene expression responses.
Many in vitro specific gene expression responses elicited by TCDD were associated with cell cycle progression and cell cycle arrest. Myc and its downstream target, cyclin D1, which forms a kinase complex with Cdk4 [43, 44] were both repressed by TCDD. In contrast, Cdkn1a, an inhibitor of cyclin-dependent kinase 2 (Cdk2)-cyclin E complex kinase activity [43] , was induced. Inactivation of the Cdk2-cyclin E complex prevents the phosphorylation of pRb resulting in cell cycle arrest during G 1 . Additionally, the in vitro induction of Btg2 suggests an alternative mechanism for cell cycle arrest during the G 2 phase. Constitutively active BTG2 in human leukemia U937 cells, induces G 2 /M cell cycle arrest by inhibiting the formation of the cyclin B1 and Cdc2 complex, thereby inhibiting the active kinase function of the complex [30] . Collectively, these results corroborate and extend previous in vitro TCDDmediated cell cycle arrest studies [45] [46] [47] [48] .
TCDD treatment resulted in a number of divergent gene responses across both models as represented by classes III and IV ( Figures 4B and 4C) . Genes related to immune cell accumulation, including major histocompatibility complex (MHC) molecules were only observed in vivo, and are likely a response to hepatic damage mediated by ROS or fatty accumulation and therefore independent of direct AhR action [19] . This is characteristic of the complex inter-action between different cell types responding to liver injury that cannot be modeled in homogenous cultures of cells.
Pharmacokinetics may also contribute to response differences between the two models. Hepa1c1c7 cells were directly treated, whereas in vivo, TCDD must first be delivered to the liver and targeted cells prior to eliciting its effects. Additionally, C57BL/6 studies were able to be carried out to 168 hrs following TCDD treatment, while in vitro studies were limited to 48 hrs to minimize potentially confounding effects due to cell confluency. However, early responses associated with classes I and II (induced or repressed in both models; Figure 4B and 4C) are well conserved and exhibit comparable levels of induction or repression in both models. Hierarchical clustering of the common active genes ( Figure 4C ) illustrates gene induction occurs early while gene repression occurs later in both models. Clustering across both time and model revealed that gene expression profiles at 1 hr in vitro and 2 hr in vivo were most similar. This clustering pattern implies that early in vitro responses may accurately model early in vivo gene expression effects.
Conclusion
Comparative analysis of global gene expression from Hepa1c1c7 cells and hepatic tissue from C57BL/6 mice identified several model-specific responses to TCDD that should be considered when extrapolating in vitro results to potential in vivo effects. Despite these differences, immortalized cells as well as other emerging in vitro systems (e.g., primary cells, stem cells and 3-D culture systems) provide valuable mechanistic information that supports the further development of high-throughput toxicity screening assays. However, the relevance of in vitro responses requires complementary in vivo verification. Furthermore, comparative studies exploiting other in vitro and in vivo systems, different structurally diverse ligands and other relevant model species will not only corroborate the relevance of the mechanisms, but will also support more appropriate extrapolations between rodent studies and potential effects in humans and ecologically-relevant species. harvested at the time of dosing (i.e. 0 hrs). For the doseresponse study, wild-type cells were treated with DMSO vehicle or 0.001, 0.01, 0.1, 1.0, 10 or 100 nM TCDD and harvested at 12 hrs. The treatment and harvesting regimen for cell culture studies are illustrated in Additional file 7.
Methods
Culture and treatment of cell lines
Animal treatment
The handling and treatment of female C57BL/6 mice has been previously described [19] . Briefly, immature ovariectomized mice were orally gavaged with 30 µg/kg TCDD for the time course study and sacrificed at 2, 4, 8, 12, 18, 24 72 or 168 hrs after treatment. For the dose-response study, mice were treated with 0.001, 0.01, 0.1, 1, 10, 100 or 300 µg/kg TCDD and sacrificed 24 hrs after dosing. Animals were sacrificed by cervical dislocation and tissue samples were removed, weighed, flash frozen in liquid nitrogen and stored at -80°C until further use.
RNA isolation
Cells were harvested by scraping in 2.0 mL of Trizol Reagent (Invitrogen). Frozen liver samples (approximately 70 mg) were transferred to 1.0 mL of Trizol Reagent and homogenized in a Mixer Mill 300 tissue homogenizer (Retsch, Germany). Total RNA from each study was isolated according to the manufacturer's protocol with an additional acid phenol:chloroform extraction. Isolated RNA was resuspended in The RNA Storage Solution (Ambion Inc., Austin, TX), quantified (A 260 ), and assessed for purity by determining the A 260 /A 280 ratio and by visual inspection of 1.0 µg on a denaturing gel.
Microarray experimental design
Changes in gene expression were assessed using customized cDNA microarrays containing 13,362 features representing 8,284 unique genes. For the time course study, TCDD-treated samples were compared to time-matched vehicle controls using an independent reference design [49] . In this design, treated Hepa1c1c7 cell or hepatic tis- Four replicates of this design were performed, each using independent cell culture samples or different animals. Dose-response changes in gene expression were analyzed using a common reference design in which samples from TCDD-treated cells or mice were co-hybridized with a common vehicle reference (i.e. independent DMSO treated Hepa1c1c7 cell samples, hepatic samples from independent sesame oil treated C57BL/6 mice) using two independent labelings (Additional file 8). Four replicates with two independent labelings were performed for both in vitro and in vivo samples. Co-hybridizations of untreated Hepa1c1c7 cells and hepatic tissue from C57BL/6 mice were performed to investigate differences in basal gene expression levels between models (Additional file 8). Four replicates were performed with two independent labelings per sample (dye swap).
Comparison of Hepalclc7 cell and C57BL/6 hepatic tissue basal gene expression
More detailed protocols regarding the microarray assay, including microarray preparation, labeling of the cDNA probe, sample hybridization and washing can be obtained from the dbZach website [50] . 
Microarray data quality assurance, normalization and analysis
Microarray data were first passed through a quality assurance protocol prior to further analysis to ensure consistently high quality data throughout the dose-response and time course studies prior to normalization and further analysis [52] . All the collected data were then normalized using a semi-parametric approach [53] . Empirical Bayes analysis was used to calculate posterior probabilities [54] . The data were filtered using a P1(t) cutoff of 0.9999 and ± 1.5 fold change to identify the most robust changes in gene expression and to obtain an initial subset of differentially regulated genes for further investigation and data interpretation. Subsequent analysis included agglomerative hierarchical and k-means clustering using the standard correlation distance metric implemented in GeneSpring 6.0 (Silicon Genetics, Redwood City, CA). Functional categorization of differentially regulated genes were mined and statistically analyzed from Gene Ontology [55] using GOMiner [56] .
Quantitative real-time PCR analysis
For each sample, 1.0 µg of total RNA was reverse transcribed by Superscript II using an anchored oligo-dT primer as described by the manufacturer (Invitrogen). The cDNA (1.0 µL) was used as a template in a 30 µL PCR reaction containing 0.1 µM of forward and reverse gene-specific primers designed using Primer 3 [57] , 3 mM MgCl 2 , 1.0 mM dNTPs, 0.025 IU AmpliTaq Gold, and 1× SYBR Green PCR buffer (Applied Biosystems, Foster City, CA). PCR amplification was conducted in MicroAmp Optical 96-well reaction plates (Applied Biosystems) on an Applied Biosystems PRISM 7000 Sequence Detection System under the following conditions: initial denaturation and enzyme activation for 10 min at 95°C, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. A dissociation protocol was performed to assess the specificity of the primers and the uniformity of the PCR-generated products. Each plate contained duplicate standards of purified PCR products of known template concentration covering 7 orders of magnitude to interpolate relative template concentrations of the samples from the standard curves of log copy number versus threshold cycle (Ct). No template controls (NTC) were also included on each plate. Samples with a Ct value within 2 standard deviations of the mean Ct values for the NTCs were considered below the limits of detection. The copy number of each unknown sample for each gene was standardized to the geometric mean of three house-keeping genes (β-actin, Gapd and Hprt) to control for differences in RNA loading, quality, and cDNA synthesis. For graphing purposes, the relative expression levels were scaled such that the expression level of the time-matched control group was equal to 1. Statistical analysis was performed with SAS 8.02 (SAS Institute, Cary, NC). Data were analyzed by analysis of variance (ANOVA) followed by Tukey's post hoc test. Differences between treatment groups were considered significant when p < 0.05. Official gene names and symbols, RefSeq and Entrez Gene IDs, forward and reverse primer sequences, and amplicon sizes are listed in Table 4 .
